Survival and Quality of Life After Liver Transplantation in Patients Aged 65 and Over

NCT ID: NCT04754503

Last Updated: 2023-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

125 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-04-09

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this non-interventional, single-center study is to assess survival and associated factors at 1 year in patients aged 65 and over who received liver transplantation

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The expected benefits of this study are to identify the preoperative risk factors of mortality from liver transplant failure in patients aged 65 and over (90-day mortality and 1 and 3-year survival) will allow better selection. candidates for this age group. In the current context of organ shortage, this study should make it possible to reduce the number of risky transplants and thus improve the allocation of grafts.Inclusion of patients who meet the inclusion criteria will be carried out during their hospitalization in the surgical department of the hepato-bilary center.

Included patients will receive a standardized geriatric assessment in addition to the usual assessment for a liver transplant.

The geriatric assessment will be carried out and conducted as follows: geriatric scores and quality of life questionnaires. Two geriatricians will perform the physical examination and blindly estimate each other's probability of survival at 90 days using a Likert scale.

Geriatricians will be blinded to hepatic data (reasons for transplantation). The consultation as well as the completion of the questionnaire will be carried out during the pre-transplantation assessment.

Survival and quality of life will be assessed at 3 and 12 months post-transplantaion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patients Suitable for a Liver Transplant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Candidates for liver transplantation
* Having expressed non-oppostion to his participation in study and documented in his medical file
* With social coverage

Exclusion Criteria

* Emergency transplant patients
* Patient already included in another study
* Patient under guardianship or curatorship
* Expressing his opposition to participate in the study
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Gérond'if

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Duron Emmanuelle, MD PhD

Role: STUDY_CHAIR

Geriatric Department, Paul Brousse Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Geriatric Department, Paul Brousse Hospital

Villejuif, Île-de-France Region, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Isabelle Dufour

Role: CONTACT

+33 (0)185781010

Prisca Lucas, PhD

Role: CONTACT

+33 (0)185781010

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Emmanuelle DURON, MD PhD

Role: primary

+33(0)145593843

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-A03063-36

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.